$11.53
Value $2.9B
CLBT and MSFT stock compared: price, dividend, valuation and results, from SEC filings.
$11.53
Value $2.9B
$523.88
Value $3.89T
Cellebrite DI (CLBT) has a market value of $2.9B and Microsoft (MSFT) $3.89T. Over the last year, with dividends, CLBT moved -27.8% and MSFT +3.3%. The P/E is 36.7 for CLBT and 27.3 for MSFT. Dividend yield: CLBT none, MSFT 0.69%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CLBT$2.9B
MSFT$3.89T
MSFT is 1,353 times CLBT
Revenue, 12 months
CLBT$476M
MSFT$346B
MSFT is 728 times CLBT
Net income, 12 months
CLBT$78M
MSFT$143B
MSFT is 1,821 times CLBT
Operating margin
CLBT14.0%
MSFT47.1%
33.1 points apart
ROIC
CLBT10.8%
MSFT28.7%
17.9 points apart
P/E
CLBT36.7
MSFT27.3
CLBT is 1.3 times MSFT
Dividend yield
CLBT0.0%
MSFT0.7%
0.7 points apart
5-year return
CLBT+8.1%
MSFT+62.1%
54.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CLBT+8.1%
MSFT+62.1%
| Period | CLBTWith dividends | MSFTWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -27.8%Price -27.8% | +3.3%Price +2.5% |
| 3 years since November 13, 2023 | +52.9%+15.2% a yearPrice +52.9% | +46.2%+13.5% a yearPrice +42.9% |
| 5 years since November 12, 2021 | +8.1%+1.6% a yearPrice +8.1% | +62.1%+10.1% a yearPrice +55.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CLBTCellebrite DIMSFTMicrosoft
| Price | $11.53 | $523.88 |
|---|---|---|
| Market value | $2.9B | $3.89T |
| Enterprise value (EV) | $2.6B | $3.93T |
| P/E | 36.7 | 27.3 |
| P/E, 5-year median | 18.2 | 35.2 |
| P/B | 5.9 | 8.3 |
| EV/EBIT | 39.1 | 24.1 |
| Free cash flow yield | 5.6% | 1.5% |
| Revenue, 12 months | $476M | $346B |
|---|---|---|
| Net income, 12 months | $78M | $143B |
| Free cash flow, 12 months | $160M | $60.0B |
| Earnings per share, 12 months | $0.31 | $19.16 |
| Revenue growth, year on year | 18.6% | 17.8% |
| Revenue growth a year, past | +19.5%over 5 years | +14.6%over 5 years |
| EPS growth a year, past | – | +17.4%over 5 years |
| Gross margin | 84.2% | 67.7% |
|---|---|---|
| Operating margin | 14.0% | 47.1% |
| Net margin | 16.5% | 41.2% |
| ROIC | 10.8% | 28.7% |
| ROE | 16.2% | 34.3% |
| Cash | $276M | $64.5B |
|---|---|---|
| Total debt | $23M | $134B |
| Net debt / EBITDA | -3.5 | 0.2 |
| Interest cover | – | 50.6× |
| Dividend yield | – | 0.7% |
|---|---|---|
| Dividend per share, 12 months | – | $3.64 |
| Dividend growth a year, past | – | +10.2%over 5 years |
| Buyback yield | – | 0.6% |
| Shareholder yield | – | 1.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Microsoft ($3.89T) is about 1,352.6 times Cellebrite DI ($2.9B), at today's prices.
Since November 12, 2021, CLBT's price moved +8.1% and MSFT's +55.6%. With dividends: CLBT +8.1% (+1.6% a year), MSFT +62.1% (+10.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Cellebrite DI and 0.69% for Microsoft. Over the last twelve months they paid – and $3.64 per share.
At today's price, the P/E is 36.7 for CLBT and 27.3 for MSFT. The median of the last five years was 18.2 and 35.2, which shows where each stands against its own past.
Over the last twelve months, the net margin was 16.5% for Cellebrite DI and 41.2% for Microsoft, and the operating margin 14.0% and 47.1%. Revenue was $476M and $346B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.